Phase II Study of IMRT With SIB as Adjuvant Treatment for High Risk Resected Well-differentiated Thyroid Cancer.

Phase II Study of Intensity-modulated Radiation (IMRT)With Simultaneous Integrated Boost (SIB) as Adjuvant Treatment for High Risk Resected Well-differentiated Thyroid Cancer.

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00279721

Enrollment

Registered

2006-01-20

Start date

2006-01-31

Completion date

2010-06-30

Last updated

2012-01-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid Neoplasms

Keywords

thyroid neoplasms, intensity modulated radiation, radiotherapy

Brief summary

Resected well-differentiated thyroid neoplasms with at least one high risk feature will receive adjuvant radiation using IMRT with SIB. The acute toxicity and locoregional control rate at 2 years will be recorded.

Detailed description

Interventions

PROCEDUREIMRT

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* resected well-differentiated throid cancer with at least one high risk feature for locoregional recurrence

Exclusion criteria

* medullary or anaplastic thyroid cancer, unresectable

Design outcomes

Primary

Measure	Time frame
toxicity according to RTOG criteria	—
locoregional control	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026